CSF1R Inhibitors

Apr 03, 2026

Summary TGCT tumors are driven by a chromosomal translocation involving chromosomes 1 and 2, which results in overexpression of colony-stimulating factor-1 (CSF-1) and promotes tumor proliferation. Currently available systemic therapies, such as Daiichi Sankyo’s TURALIO and Ono Pharma’s ROMVIMZA, provide opt...

Mar 03, 2025

Ono Pharmaceuticals received FDA approval on 14 February 2025 for vimseltinib, a treatment for tenosynovial giant cell tumor (TGCT), which will be sold under the brand name ROMVIMZA. This approval positions Ono in direct competition with fellow Japanese pharmaceutical company Daiichi Sankyo in the TGCT market. ...